signature=de9c9b3d4c37819e380eb039fec779f5,A stroma-related gene signature predicts resistance to ne...

1

Colleoni, M. et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 10, 6622–6628 (2004).

2

Guarneri, V. et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 24, 1037–1044 (2006).

3

Fisher, E.R. et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95, 681–695 (2002).

4

Chang, J.C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362–369 (2003).

5

Gianni, L. et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23, 7265–7277 (2005).

6

Hess, K.R. et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin and cyclophosphamide in breast cancer. J. Clin. Oncol. 24, 4236–4244 (2006).

7

Thuerigen, O. et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin and docetaxel in primary breast cancer. J. Clin. Oncol. 24, 1839–1845 (2006).

8

Hannemann, J. et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 23, 3331–3342 (2005).

9

Potti, A. et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12, 1294–1300 (2006).

10

Bonnefoi, H. et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00–01 clinical trial. Lancet Oncol. 8, 1071–1078 (2007).

11

Farmer, P. et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24, 4660–4671 (2005).

12

Perou, C.M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).

13

Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869–10874 (2001).

14

Sotiriou, C. et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98, 262–272 (2006).

15

van de Vijver, M.J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).

16

Bild, A.H., Potti, A. & Nevins, J.R. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer 6, 735–741 (2006).

17

Hu, Z. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).

18

Boersma, B.J. et al. A stromal gene signature associated with inflammatory breast cancer. Int. J. Cancer 122, 1324–1332 (2008).

19

Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253–1270 (2003).

20

Mani, S.A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).

21

Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100, 672–679 (2008).

22

West, R.B. et al. Determination of stromal signatures in breast carcinoma. PLoS Biol. 3, e187 (2005).

23

Wirapati, P. et al. Meta-analysis of gene-expression profiles in breast cancer: toward a unified understanding of breast cancer sub-typing and prognosis signatures. Breast Cancer Res. 10, R65 (2008).

24

Qiu, W. et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat. Genet. 40, 650–655 (2008).

25

Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518–527 (2008).

26

Weaver, V.M. et al. β4 integrin–dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2, 205–216 (2002).

27

Misra, S., Ghatak, S. & Toole, B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 280, 20310–20315 (2005).

28

Damiano, J.S., Cress, A.E., Hazlehurst, L.A., Shtil, A.A. & Dalton, W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658–1667 (1999).

29

Hazlehurst, L.A. et al. Reduction in drug-induced DNA double-strand breaks associated with β1 integrin–mediated adhesion correlates with drug resistance in U937 cells. Blood 98, 1897–1903 (2001).

30

McAllister, S.S. et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133, 994–1005 (2008).

31

Hedges, L. & Olkin, I. Statistical Methods for Meta-Analysis. 39 (Academic Press, London, 1985).

32

Westfall, P. & Young, S. Resampling-Based Multiple Testing: Examples And Methods For P-Values Adjustment. Ch.2 (Wiley, New York, 1993).

33

Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. [Ser B] 57, 289–300 (1995).

34

R Development Core Team. R: A language and environment for statistical computing. (R Foundation for Statistical Computing, Vienna, 2005).

35

International Union Against Cancer (UICC). TNM Classification of Malignant Tumours 5th edn. (eds. Sobin, L.H. & Wittekind, C.) (Wiley, New York, 1997).

36

Finak, G. et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res. 8, R58 (2006).